Amarin Corp Plc (AMRN)

[dogn]

Most likely EVAPORATE used mineral oil placebo for consistency with REDUCE-IT trial.

Deterioration in placebo arm assumed due to untreated plaque progression, placebo assumed to be inert

Authors of Evaporate previously "demonstrated that progression rates on mineral oil placebo is similar to non-mineral oil placebo cohort using same methodology, scanner and laboratory."

Text from conclusion slide at https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=bb727249a4bd45dcb9ed91b45bd5957c (non-mineral oil cohort GARLIC5 trial, compared to EVAPORATE in 3rd from last slide "Analysis of Covariance for Log_FU_Sum_TotPlaq_mm3"

(slides from Related Content section of https://www.acc.org/latest-in-cardiology/clinical-trials/2019/11/15/17/46/evaporate)

The EVAPORATE trial publication at https://academic.oup.com/eurheartj/article/41/40/3925/5898836 has been cited 233 times according to Google Scholar https://scholar.google.com/scholar?hl=en&as_sdt=0%2C15&q=EVAPORATE+budoff